Innoviva, Inc. INVA Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Cost Reimbursement | $0-100% | $0— | $1.3M— | $800K— | $600K— | |
| Giapreza | $20.23M+10.7% | $19.55M+21.6% | $18.46M+34.0% | $17.33M+32.2% | $18.27M+51.3% | |
| Royalty | $55.17M-4.6% | $54.9M-12.2% | $59.9M+5.0% | $63.88M+0.2% | $57.81M-1.0% | |
| Xacduro | $18.07M+132% | $32.07M+378% | $23.81M+143% | $10.73M+358% | $7.78M+248% | |
| Percentage Of Royalty Payable On Net Sales by Product | ||||||
| Giapreza | 6%0.0pp | —— | —— | —— | 6%+4.5pp | |
| Royalty Expense by Product | ||||||
| Durlobactam | $0— | $0— | $0— | $0— | $0— | |
| Giapreza | $1.3M+18.2% | $1.2M+33.3% | $1.1M+10.0% | $1.1M+57.1% | $1.1M+37.5% | |
| Research And Development Expense by Product | ||||||
| External Services | $2.61M-14.6% | $3.01M+11.1% | $2.86M+18.3% | $6.78M+977% | $3.05M+85.0% | |
| Internal Expenses | $2.64M+95.9% | $1.55M+61.5% | $1.44M+27.2% | $1.2M-37.8% | $1.35M-39.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Innoviva, Inc. break its business down?
- Innoviva, Inc. (INVA) reports revenue by product across 4 parts — Cost Reimbursement, Giapreza, Royalty and Xacduro. Each is extracted from the segment footnotes and tracked over time.
- Where does Innoviva, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Innoviva, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.